Literature DB >> 28077994

Reverse screening approach to identify potential anti-cancer targets of dipyridamole.

Shu-Min Ge1, Dong-Ling Zhan2, Shu-Hua Zhang1, Li-Qiang Song1, Wei-Wei Han3.   

Abstract

Dipyridamole (DIP) inhibits thrombus formation when given chronically, and causes vasodilation over a short time. To date, DIP can increase the anticancer drugs (5-fluorouracil, methotrexate, piperidine, vincristine) concentration in cancer cells and hence enhance the efficacy of treatment cancer. The inhibition of DIP may result in increased 5-fluorouracil efficacy and diminish the drug side effects. But the actual molecular targets remain unknown. In this study, reverse protein-ligands docking, and quantum mechanics were used to search for the potential molecular targets of DIP. The quantum mechanics calculation was performed by using Gaussian 03 program package. Reverse pharmacophore mapping was used to search for potential molecular target candidates for a given small molecule. The docking study was used for exploring the potential anti-cancer targets of dipyridamole. The two predicted binders with the statistically significant prediction are dihydropyrimidine dehydrogenase (DPD) (PDB Id: 1GTE) and human spindle checkpoint kinase Bub1 (PDB Id: 3E7E). Structure analysis suggests that electrostatic interaction and hydrogen bonding play an important role in their binding process. The strong functional linkage of DIP and 5FU supports our prediction. In conclusion, these results generate a tractable set of anticancer proteins. The exploration of polypharmacology will provide us new opportunities in treating systematic diseases, such as the cancers. The results would generate a tractable set of anticancer target proteins for future experimental validations.

Entities:  

Keywords:  Dipyridamole; anticancer target proteins; reverse protein-ligand docking

Year:  2016        PMID: 28077994      PMCID: PMC5209474     

Source DB:  PubMed          Journal:  Am J Transl Res            Impact factor:   4.060


  30 in total

1.  Organic solvents order the dynamic switch II in Ras crystals.

Authors:  Greg Buhrman; Vesna de Serrano; Carla Mattos
Journal:  Structure       Date:  2003-07       Impact factor: 5.006

2.  Intracellular adenosine inhibits IgE-dependent degranulation of human skin mast cells.

Authors:  Gregorio Gomez; Vincent Nardone; Sahar Lotfi-Emran; Wei Zhao; Lawrence B Schwartz
Journal:  J Clin Immunol       Date:  2013-11       Impact factor: 8.317

3.  Chemoprevention activity of dipyridamole in the MMTV-PyMT transgenic mouse model of breast cancer.

Authors:  Chunmei Wang; Luciana P Schwab; Meiyun Fan; Tiffany N Seagroves; John K Buolamwini
Journal:  Cancer Prev Res (Phila)       Date:  2013-02-27

4.  Crystal structure of the productive ternary complex of dihydropyrimidine dehydrogenase with NADPH and 5-iodouracil. Implications for mechanism of inhibition and electron transfer.

Authors:  Doreen Dobritzsch; Stefano Ricagno; Gunter Schneider; Klaus D Schnackerz; Ylva Lindqvist
Journal:  J Biol Chem       Date:  2002-01-16       Impact factor: 5.157

5.  Increased expression of mitotic checkpoint genes in breast cancer cells with chromosomal instability.

Authors:  Bibo Yuan; Yi Xu; Ju-Hyung Woo; Yunyue Wang; Young Kyung Bae; Dae-Sung Yoon; Robert P Wersto; Ellen Tully; Kathleen Wilsbach; Edward Gabrielson
Journal:  Clin Cancer Res       Date:  2006-01-15       Impact factor: 12.531

6.  Structure and substrate recruitment of the human spindle checkpoint kinase Bub1.

Authors:  Jungseog Kang; Maojun Yang; Bing Li; Wei Qi; Chao Zhang; Kevan M Shokat; Diana R Tomchick; Mischa Machius; Hongtao Yu
Journal:  Mol Cell       Date:  2008-11-07       Impact factor: 17.970

7.  PharmMapper server: a web server for potential drug target identification using pharmacophore mapping approach.

Authors:  Xiaofeng Liu; Sisheng Ouyang; Biao Yu; Yabo Liu; Kai Huang; Jiayu Gong; Siyuan Zheng; Zhihua Li; Honglin Li; Hualiang Jiang
Journal:  Nucleic Acids Res       Date:  2010-04-29       Impact factor: 16.971

8.  Dipyridamole increases the cytotoxicity of cisplatin in human larynx cancer cells in vitro.

Authors:  M Rodrigues; F Barbosa; J R Perussi
Journal:  Braz J Med Biol Res       Date:  2004-03-23       Impact factor: 2.590

9.  Effect of concomitant oral chronic dipyridamole therapy on inflammatory cytokines in heart failure patients.

Authors:  Silvia Del Ry; Maria Aurora Morales; Maria Chiara Scali; Alessandro Tafi; Carlo Giustarini; Federico Posteraro; Vittorio Ambrosini; Marco Agrusta; Eugenio Picano; Rosa Sicari
Journal:  Clin Lab       Date:  2013       Impact factor: 1.138

10.  Regadenoson and adenosine are equivalent vasodilators and are superior than dipyridamole- a study of first pass quantitative perfusion cardiovascular magnetic resonance.

Authors:  Sujethra Vasu; W Patricia Bandettini; Li-Yueh Hsu; Peter Kellman; Steve Leung; Christine Mancini; Sujata M Shanbhag; Joel Wilson; Oscar Julian Booker; Andrew E Arai
Journal:  J Cardiovasc Magn Reson       Date:  2013-09-24       Impact factor: 5.364

View more
  4 in total

1.  Dipyridamole induces the phosphorylation of CREB to promote cancer cell proliferation.

Authors:  Lina Abdelghany; Nageh El-Mahdy; Tsuyoshi Kawabata; Shinji Goto; Tao-Sheng Li
Journal:  Oncol Lett       Date:  2021-02-03       Impact factor: 2.967

2.  Gene set enrichment analysis and meta-analysis to identify six key genes regulating and controlling the prognosis of esophageal squamous cell carcinoma.

Authors:  Wenwu He; Linxin Chen; Kun Yuan; Qiuxi Zhou; Lin Peng; Yongtao Han
Journal:  J Thorac Dis       Date:  2018-10       Impact factor: 2.895

Review 3.  Reverse Screening Methods to Search for the Protein Targets of Chemopreventive Compounds.

Authors:  Hongbin Huang; Guigui Zhang; Yuquan Zhou; Chenru Lin; Suling Chen; Yutong Lin; Shangkang Mai; Zunnan Huang
Journal:  Front Chem       Date:  2018-05-09       Impact factor: 5.221

4.  Reverse pharmacophore mapping and molecular docking studies for discovery of GTPase HRas as promising drug target for bis-pyrimidine derivatives.

Authors:  Sanjiv Kumar; Jagbir Singh; Balasubramanian Narasimhan; Syed Adnan Ali Shah; Siong Meng Lim; Kalavathy Ramasamy; Vasudevan Mani
Journal:  Chem Cent J       Date:  2018-10-22       Impact factor: 4.215

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.